Veklury Takes Gilead Earnings On Wild Ride
Third Quarter Sales Were Up But Veklury Missed Some Estimates
The company is narrowing its 2020 guidance, citing COVID-19’s unpredictability and its effects on Veklury’s sales.
You may also be interested in...
US FDA will hold 10 December advisory committee on Pfizer/BioNTech's just-filed application; the WHO issued a recommendation against Gilead's Veklury for hospitalized patients.
The global health crisis has presented a chance for the industry to improve its reputation by highlighting the value of its R&D engines. Pharma execs and observers talk to Scrip about why they are optimistic about industry’s chance to regain public trust.
Third quarter earnings show Gilead’s Immunomedics buy paid off, but filgotinib’s path may narrow. The HIV and HCV franchises picked up from their COVID-19 lull.